Linperlisib plus CHOP for newly diagnosed T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding the targeted drug linperlisib to standard chemotherapy (CHOP) can help adults with certain types of peripheral T-cell lymphoma that haven't been treated yet. It aims to see if the combination works better than CHOP alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a specific type of T-cell lymphoma that is newly diagnosed and hasn't been treated yet.
- You have at least one tumor that can be measured on a scan and is larger than 1.5 cm.
- You are willing to provide a tumor tissue sample from a previous biopsy or get a new one.
- Your overall health is good enough for daily activities (ECOG score 0-2).
- Your heart, liver, kidney, and blood counts meet certain minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests linperlisib (a medicine that targets a cell-growth pathway) together with CHOP chemotherapy in people with peripheral T-cell lymphoma that has not been treated before. It may help shrink the lymphoma and control the disease by combining two approaches.
This trial is testing a combination of two targeted drugs (linperlisib and an EZH2 inhibitor) for people whose peripheral T-cell lymphoma has come back or not responded to previous treatment. The goal is to see if this new combination can help shrink tumors and slow the disease.
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
This trial tests whether adding belinostat or pralatrexate to standard chemotherapy (CHOP) works better than CHOP alone for people newly diagnosed with peripheral T-cell lymphoma (PTCL). It aims to find a more effective first treatment option.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.